BeStock  
Markets › Compare › JBIO vs GPCR

JBIO vs GPCR

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
JBIO · Jade Biosciences$15.31 ▲ 1.66%
GPCR · Structure Therapeutics$16.13 ▼ 5.78%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

3294156217279Nov 24, '25May 26, '26Nov 20, '26
  • JBIO +26.0%
  • GPCR -54.3%

Head to head

MetricJBIOGPCR
Price$15.31$16.13
Change today▲ 1.66%▼ 5.78%
Market cap$1.06B$1.15B
Return, 3 months-28.2%-67.1%
Return, year to date-0.8%-76.8%
Return, 1 year+27.6%-53.0%
P/E (TTM)––
P/B2.30.9
P/E percentile vs own 5y11th99th
Dividend yield––
Revenue growth (YoY, latest qtr)––
Net profit growth (YoY)-39.2%-120.3%
Gross margin––
Operating margin––
Net margin––
Return on equity-51.4%-29.5%
Analyst target vs. price+244.0%+542.7%
Analyst buy share100%100%
RSI (14)5122
30-day volatility53.3%61.9%
Max drawdown, 1 year-50.1%-82.8%
Trend readLeaning bullishStrong downtrend
Analyst consensusBuyBuy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • GPCR is the largest of the group by market value.
  • JBIO has returned the most over the past year.
  • JBIO has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top